Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals
Breast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum o...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2020-11-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2020.586268/full |
| _version_ | 1828498294858317824 |
|---|---|
| author | Andrea Feliciano Lucila González Yoelsis Garcia-Mayea Cristina Mir Mireia Artola Nieves Barragán Remedios Martín Anna Altés Josep Castellvi Sergi Benavente Santiago Ramón y Cajal Martín Espinosa-Bravo Javier Cortés Javier Cortés Isabel T. Rubio Matilde E. LLeonart Matilde E. LLeonart |
| author_facet | Andrea Feliciano Lucila González Yoelsis Garcia-Mayea Cristina Mir Mireia Artola Nieves Barragán Remedios Martín Anna Altés Josep Castellvi Sergi Benavente Santiago Ramón y Cajal Martín Espinosa-Bravo Javier Cortés Javier Cortés Isabel T. Rubio Matilde E. LLeonart Matilde E. LLeonart |
| author_sort | Andrea Feliciano |
| collection | DOAJ |
| description | Breast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs. 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based on the expression levels of five microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the overexpression and downregulation of proteins differently expressed in the serum of breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a, miR-497, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and miR-451 was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16 with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and the potential use of the predictor here described are discussed. |
| first_indexed | 2024-12-11T13:03:23Z |
| format | Article |
| id | doaj.art-2323d22a0b5345ba9b9922f9ab5bb7a7 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-11T13:03:23Z |
| publishDate | 2020-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-2323d22a0b5345ba9b9922f9ab5bb7a72022-12-22T01:06:23ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2020-11-011010.3389/fonc.2020.586268586268Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy IndividualsAndrea Feliciano0Lucila González1Yoelsis Garcia-Mayea2Cristina Mir3Mireia Artola4Nieves Barragán5Remedios Martín6Anna Altés7Josep Castellvi8Sergi Benavente9Santiago Ramón y Cajal10Martín Espinosa-Bravo11Javier Cortés12Javier Cortés13Isabel T. Rubio14Matilde E. LLeonart15Matilde E. LLeonart16Biomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainBiomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainBiomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainBiomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainPrimary Care Center CAP-Vallcarca-Sant Gervasi, Barcelona, SpainPrimary Care Center CAP-Vallcarca-Sant Gervasi, Barcelona, SpainPrimary Care Center CAP-Vallcarca-Sant Gervasi, Barcelona, SpainPrimary Care Center CAP-Vallcarca-Sant Gervasi, Barcelona, SpainBiomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainBiomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainBiomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainBreast Pathology Unit, Vall d'Hebron University Hospital, Barcelona, SpainInstitute of Breast Cancer, Quiron Group, Barcelona, SpainVall d'Hebron Institute of Oncology (VHIO), Barcelona, SpainBreast Surgical Oncology, University of Navarra Clinic, Madrid, SpainBiomedical Research in Cancer Stem Cells Group, Vall d'Hebron Research Institute (VHIR), Universitat Autònoma de Barcelona, Barcelona, SpainSpanish Biomedical Research Network Center in Oncology, Madrid, SpainBreast cancer is the cancer with the most incidence and mortality in women. microRNAs are emerging as novel prognosis/diagnostic tools. Our aim was to identify a serum microRNA signature useful to predict cancer development. We focused on studying the expression levels of 30 microRNAs in the serum of 96 breast cancer patients vs. 92 control individuals. Bioinformatic studies provide a microRNA signature, designated as a predictor, based on the expression levels of five microRNAs. Then, we tested the predictor in a group of 60 randomly chosen women. Lastly, a proteomic study unveiled the overexpression and downregulation of proteins differently expressed in the serum of breast cancer patients vs. that of control individuals. Twenty-six microRNAs differentiate cancer tissue from healthy tissue, and 16 microRNAs differentiate the serum of cancer patients from that of the control group. The tissue expression of miR-99a, miR-497, miR-362, and miR-1274, and the serum levels of miR-141 correlated with patient survival. Moreover, the predictor consisting of miR-125b, miR-29c, miR-16, miR-1260, and miR-451 was able to differentiate breast cancer patients from controls. The predictor was validated in 20 new cases of breast cancer patients and tested in 60 volunteer women, assigning 11 out of 60 women to the cancer group. An association of low levels of miR-16 with a high content of CD44 protein in serum was found. Circulating microRNAs in serum can represent biomarkers for cancer prediction. Their clinical relevance and the potential use of the predictor here described are discussed.https://www.frontiersin.org/articles/10.3389/fonc.2020.586268/fullbreast cancerserummicroRNAsprognosisdiagnosis |
| spellingShingle | Andrea Feliciano Lucila González Yoelsis Garcia-Mayea Cristina Mir Mireia Artola Nieves Barragán Remedios Martín Anna Altés Josep Castellvi Sergi Benavente Santiago Ramón y Cajal Martín Espinosa-Bravo Javier Cortés Javier Cortés Isabel T. Rubio Matilde E. LLeonart Matilde E. LLeonart Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals Frontiers in Oncology breast cancer serum microRNAs prognosis diagnosis |
| title | Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals |
| title_full | Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals |
| title_fullStr | Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals |
| title_full_unstemmed | Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals |
| title_short | Five microRNAs in Serum Are Able to Differentiate Breast Cancer Patients From Healthy Individuals |
| title_sort | five micrornas in serum are able to differentiate breast cancer patients from healthy individuals |
| topic | breast cancer serum microRNAs prognosis diagnosis |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2020.586268/full |
| work_keys_str_mv | AT andreafeliciano fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT lucilagonzalez fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT yoelsisgarciamayea fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT cristinamir fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT mireiaartola fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT nievesbarragan fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT remediosmartin fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT annaaltes fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT josepcastellvi fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT sergibenavente fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT santiagoramonycajal fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT martinespinosabravo fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT javiercortes fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT javiercortes fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT isabeltrubio fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT matildeelleonart fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals AT matildeelleonart fivemicrornasinserumareabletodifferentiatebreastcancerpatientsfromhealthyindividuals |